Palvella Therapeutics Inc (PVLA) Actualités

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of

Presentation highlighted the recent expansion of the Phase 3 SELVA trial to include children 3 to 5 years old...

Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

WAYNE, Pa., April 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a...

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology

WAYNE, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated...

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a...

Form 8-K - Current report

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

WAYNE, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

Expansion reflects Palvella's commitment to serving all patients affected by microcystic lymphatic...